BioCentury
ARTICLE | Clinical News

XaraColl regulatory update

January 3, 2017 9:18 PM UTC

FDA issued a refusal to file letter for an NDA from Innocoll for XaraColl bupivacaine collagen-matrix implants to treat postsurgical pain. According to the company, FDA said the NDA was “not sufficien...

BCIQ Company Profiles

Innocoll Holdings Ltd.